Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)
1.8800 x 1 1.9900 x 24
Post-market by (Cboe BZX)
1.9300 +0.0900 (+4.89%) 04/21/25 [NASDAQ]
1.8800 x 1 1.9900 x 24
Post-market 1.9500 +0.0200 (+1.04%) 18:00 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.8100
Day High
1.9900
Open 1.8200
Previous Close 1.8400 1.8400
Volume 1,194,500 1,194,500
Avg Vol 1,136,140 1,136,140
Stochastic %K 34.92% 34.92%
Weighted Alpha -26.49 -26.49
5-Day Change +0.0200 (+1.05%) +0.0200 (+1.05%)
52-Week Range 1.0400 - 3.9300 1.0400 - 3.9300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 280,287
  • Shares Outstanding, K 152,330
  • Annual Sales, $ 144,290 K
  • Annual Income, $ -13,580 K
  • EBIT $ -12 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.39
  • Price/Sales 1.94
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 120.95% ( -255.47%)
  • Historical Volatility 63.82%
  • IV Percentile 75%
  • IV Rank 28.48%
  • IV High 376.42% on 04/17/25
  • IV Low 19.22% on 09/09/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 5,518
  • Volume Avg (30-Day) 421
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 25,356
  • Open Int (30-Day) 26,237

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.01
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.02
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6500 +16.97%
on 04/09/25
Period Open: 2.3800
2.4593 -21.52%
on 03/24/25
-0.4500 (-18.91%)
since 03/21/25
3-Month
1.5900 +21.38%
on 01/22/25
Period Open: 1.6300
2.6800 -27.99%
on 03/05/25
+0.3000 (+18.40%)
since 01/21/25
52-Week
1.0400 +85.58%
on 11/12/24
Period Open: 2.6400
3.9300 -50.89%
on 06/12/24
-0.7100 (-26.89%)
since 04/19/24

Most Recent Stories

More News
Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics: Q4 Earnings Snapshot

HRTX : 1.9300 (+4.89%)
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 1.9300 (+4.89%)
Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics: Q2 Earnings Snapshot

HRTX : 1.9300 (+4.89%)
Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics: Q1 Earnings Snapshot

HRTX : 1.9300 (+4.89%)
Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics: Q4 Earnings Snapshot

HRTX : 1.9300 (+4.89%)
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 1.9300 (+4.89%)
Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics: Q2 Earnings Snapshot

HRTX : 1.9300 (+4.89%)
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of...

HRTX : 1.9300 (+4.89%)
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 1.9300 (+4.89%)
Heron Therapeutics Announces Cost Reduction Plan and Restructuring

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 1.9300 (+4.89%)

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

3rd Resistance Point 2.1900
2nd Resistance Point 2.0900
1st Resistance Point 2.0100
Last Price 1.9300
1st Support Level 1.8300
2nd Support Level 1.7300
3rd Support Level 1.6500

See More

52-Week High 3.9300
Fibonacci 61.8% 2.8260
Fibonacci 50% 2.4850
Fibonacci 38.2% 2.1440
Last Price 1.9300
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro